No Data
IDEAYA Biosciences Initiates Subject Dosing in Phase I Bladder Cancer Trial
Express News | IDEAYA Biosciences Announces First-Patient-in for Phase 1 Clinical Trial Evaluating Ide397 and Trodelvy® Combination in Mtap-Deletion Bladder Cancer
Express News | IDEAYA Biosciences: Targeting Ide397 Phase 2 Monotherapy Expansion Dose Clinical Data Update in H2
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
Citi's North America Focus List Updated, Adds: Coca-Cola, Evergy, Etc.
Express News | Ideaya Biosciences: JPMorgan raised its target price from $55 to $65.